Showing 2111-2120 of 9130 results for "".
Kythera's Kybella Approved; ASLMS Update
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-kythera-s-kybella-approved-aslms-update/18925/FDA Approves Kythera's Kybella (ATX-101 or deoxycholic acid) injection for reduction of sub mental fullness or double chin. ASLMS Recognizes women in device-based medicine (Women in Energy-based Devices). Deka and Syneron get new clearances. ASDS Launches Skin Cancer PSAs, and Foamix sells shares.Atopic Dermatitis Guidelines Update
https://practicaldermatology.com/topics/general-topics/atopic-dermatitis-guidelines-update/18949/Peter Lio, MD speaks with Joel Cohen, MD about atopic dermatitis consensus recommendations, particularly the differences among different medical specialties. He also discusses how global guidelines may begin to take shape.Valeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/videos/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.2014 Year in Review: Skin Cancer
https://practicaldermatology.com/topics/skin-cancer-photoprotection/2014-year-in-review-skin-cancer/19001/Gary Goldenberg, MD offers a snapshot look at the newest therapies in the skin cancer treatment landscape, as well as the newest innovations across various disease states in the specialty.Periorbital Rejuvenation Trends
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/periorbital-rejuvenation-trends/19046/Brian Biesman, MD talks about assessment of the aging face and approaches for periorbital rejuvenation.Allergan Strikes $66 Billion Deal with Actavis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-allergan-strikes-66-billion-deal-with-actavis/19021/In this edition of DermWireTV, host Ranna Jaraha discusses this week's blockbuster merger deal between Allergan and Actavis. Also featured in this edition is a new report detailing the rising costs of treating skin cancer, and high recognition for a dermatologic device manufacturer.Acquiring An Education In Cosmetic Dermatology
https://practicaldermatology.com/topics/practice-management/acquiring-an-education-in-cosmetic-dermatology/19024/With many residency programs not emphasizing cosmetic dermatology, Kristina Goldenberg, MD gives advice on how to be proactive in achieving an education in aesthetics.No One Right Way to Treat a Patient
https://practicaldermatology.com/topics/practice-management/no-one-right-way-to-treat-a-patient/19026/Recounting experiences in residency, Kristina Goldenberg, MD talks about the importance of synthesizing various approaches and styles of practice from mentors.Understanding Sublative Therapy
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/understanding-sublative-therapy/19056/What is sublative? Michael H. Gold, MD explains how the technology works and how it fits in practice.Beware of International Injectables
https://practicaldermatology.com/topics/practice-management/beware-of-international-injectables/19053/Julie Woodward, MD. Associate Professor of Ophthalmology Associate Professor in Dermatology; Chief, Oculoplastic and Reconstructive Surgery Service, Duke University Medical Center, addresses the challenges that arise when patients receive unknown injectables overseas. Complications from improperly u